Pharmacological characterization of repeated corticosterone injection-induced depression model in rats

Brain Research

Volumn 1359, Issue , 2010, Pages 75-80

  Iijima, Michihiko ^a   Ito, Akie ^a   Kurosu, Shinsuke ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Corticosterone; Forced swimming; Glucocorticoid; HPA axis; Psychotic major depression

Indexed keywords

CORTICOSTERONE; FLUVOXAMINE; IMIPRAMINE; MIFEPRISTONE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPSYCHOTIC AGENTS; CORTICOSTERONE; DEPRESSIVE DISORDER, MAJOR; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RATS;

ANIMALIA; RATTUS; RODENTIA;

EID: 77958014361     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.08.078     Document Type: Article

References (31)

1. Y. Ago, S. Arikawa, M. Yata, K. Yano, M. Abe, K. Takuma, and T. Matsuda Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression Neuropharmacology 55 2008 1355 1363
2. B. Aisa, R. Tordera, B. Lasheras, J. Del Río, and M.J. Ramírez Effects of maternal separation on hypothalamic-pituitary-adrenal responses, cognition and vulnerability to stress in adult female rats Neuroscience 154 2008 1218 1226
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th Edition 2000 Washington DC American Psychiatric Press
4. J.K. Belanoff, B.H. Flores, M. Kalezhan, B. Sund, and A.F. Schatzberg Rapid reversal of psychotic depression using mifepristone J. Clin. Psychopharmacol. 21 2001 516 521
5. J.K. Belanoff, A.J. Rothschild, F. Cassidy, C. DeBattista, E.E. Baulieu, C. Schold, and A.F. Schatzberg An open label trial of C-1073 (mifepristone) for psychotic major depression Biol. Psychiatry 52 2002 386 392
6. T.K. Birkenhager, W.W. van den Broek, P.G. Mulder, P. Moleman, and J.A. Bruijn Efficacy of imipramine in psychotic versus nonpsychotic depression J. Clin. Psychopharmacol. 28 2008 166 170
7. F. Contreras, J.M. Menchon, M. Urretavizcaya, M.A. Navarro, J. Vallejo, and G. Parker Hormonal differences between psychotic and non-psychotic melancholic depression J. Affect. Disord. 100 2007 65 73
8. D.J. David, B.A. Samuels, Q. Rainer, J.W. Wang, D. Marsteller, I. Mendez, M. Drew, D.A. Craig, B.P. Guiard, J.P. Guilloux, R.P. Artymyshyn, A.M. Gardier, C. Gerald, I.A. Antonijevic, E.D. Leonardo, and R. Hen Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression Neuron 62 2009 479 493
9. C. DeBattista, J. Belanoff, S. Glass, A. Khan, R.L. Horne, C. Blasey, L.L. Carpenter, and G. Alva Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression Biol. Psychiatry 60 2006 1343 1349
10. A. Dhir, and S.K. Kulkarni Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors Neurosci. Lett. 445 2008 83 88
11. B.H. Flores, H. Kenna, J. Keller, H.B. Solvason, and A.F. Schatzberg Clinical and biological effects of mifepristone treatment for psychotic depression Neuropsychopharmacology 31 2006 628 636 (Pubitemid 43276978)
12. F. Gatti, L. Bellini, M. Gasperini, J. Perez, R. Zanardi, and E. Smeraldi Fluvoxamine alone in the treatment of delusional depression Am. J. Psychiatry 153 1996 414 416
13. Z. Górka, and K. Janus Effects of neuroleptics displaying antidepressant activity on behavior of rats in the forced swimming test Pharmacol. Biochem. Behav. 23 1985 203 206
14. A. Gregus, A.J. Wintink, A.C. Davis, and L.E. Kalynchuk Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats Behav. Brain Res. 156 2005 105 114
15. S.K. Hemrick-Luecke, and D.C. Evans Comparison of the potency of MDL 100, 907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis Neuropharmacology 42 2002 162 169
16. S.A. Johnson, N.M. Fournier, and L.E. Kalynchuk Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor Behav. Brain Res. 168 2006 280 288
17. J. Keller, B. Flores, R.G. Gomez, H.B. Solvason, H. Kenna, G.H. Williams, and A.F. Schatzberg Cortisol circadian rhythm alterations in psychotic major depression Biol. Psychiatry 60 2006 275 281
18. A. Khan, C. Noonan, and W. Healey Is a single tricyclic antidepressant trial and active treatment for psychotic depression? Prog. Neuropsychopharmacol. Biol. Psychiatry 15 1991 765 770
19. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders Neuropsychopharmacology 28 2003 402 412
20. P. Martin, P. Soubrié, and A.J. Puech Reversal of helpless behavior by serotonin uptake blockers in rats Psychopharmacology (Berl) 101 1990 403 407
21. J.L. Mayer, L. Klumpers, S. Maslam, E.R. de Kloet, M. Joëls, and P.J. Lucassen Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis J. Neuroendocrinol. 18 2006 629 631
22. M.M. Ohayon, and A.F. Schatzberg Prevalence of depressive episodes with psychotic features in the general population Am. J. Psychiatry 159 2002 1855 1861
23. C.A. Oomen, J.L. Mayer, E.R. de Kloet, M. Joëls, and P.J. Lucassen Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the reduction in neurogenesis after chronic stress Eur. J. Neurosci. 26 2007 3395 3401
24. T. Owashi, T. Otsubo, A. Oshima, K. Nakagome, T. Higuchi, and K. Kamijima Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression Psychoneuroendocrinology 33 2008 152 161
25. R.D. Romeo Adolescence: a central event in shaping stress reactivity Dev. Psychobiol. 52 2010 244 253
26. A.J. Rothschild, J.A. Samson, M.P. Bessette, and J.T. Carter-Campbell Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression J. Clin. Psychiatry 54 1993 338 342
27. A.F. Schatzberg New approaches to managing psychotic depression J. Clin. Psychiatry 64 2003 19 23
28. A. Schmitt, and D.F. Braus [Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy] Dtsch Med. Wochenschr. 125 2000 1526 1529
29. Y.I. Sheline, P.W. Wang, M.H. Gado, J.G. Csernansky, and M.W. Vannier Hippocampal atrophy in recurrent major depression Proc. Natl Acad. Sci. USA 93 1996 3908 3913
30. 2A receptor levels Exp. Neurol. 218 2009 83 91
31. R. Zanardi, L. Franchini, A. Serretti, J. Perez, and E. Smeraldi Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study J. Clin. Psychiatry 61 2000 26 29